Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shin Nippon Biomedical Laboratories reported a 5.3% increase in revenue for the six months ending September 2024, reaching 12,508 million yen, despite a significant drop in operating profit by 96.6%. The company’s net assets grew to 36,453 million yen, although the equity ratio decreased to 40.9%. Dividends for the fiscal year are forecasted to remain stable at 50 yen per share.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.